Understanding Tysabri and Progressive Multifocal Leukoencephalopathy: What Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Surveillance to Targeted Occupational Risk

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, vision changes, or weakness, you may be concerned about progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance research have established PML as a known risk of certain immunosuppressive therapies, including Tysabri. This page provides an objective overview of PML symptoms, FDA warnings, and what current science says about monitoring and risk factors.

Tysabri and PML: A Documented Association

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies three risk factors that increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can be variable. A retrospective national cohort study of 456 Italian PML cases observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). PML is a severe demyelinating disease that can lead to progressive neurological deficits. Common symptoms include cognitive changes, motor weakness, gait disturbance, and visual impairments. Because these symptoms can overlap with multiple sclerosis relapses, diagnosis requires a high index of suspicion and appropriate testing, including brain MRI and detection of JCV DNA in cerebrospinal fluid.

Mechanistic Pathway Linking Tysabri to PML

The mechanistic pathway linking Tysabri to PML involves the drug's mechanism of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs normal immune surveillance. In the setting of reduced immune cell trafficking, JCV can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, as this indicates prior exposure to the virus.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The boxed warning explicitly states that TYSABRI increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also instructs that TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, patients who develop PML may face significant challenges. The disease usually leads to death or severe disability, and early detection is critical for improving outcomes. If a patient experiences symptoms that are not promptly recognized as potential PML, or if risk factors are not adequately assessed before and during treatment, there may be grounds for legal consideration.

Attorney Considerations for Affected Patients

Attorney-related considerations for affected patients include the need to evaluate whether the prescribing physician adequately discussed the risks of PML with the patient before starting Tysabri, and whether appropriate monitoring was performed. The TOUCH Prescribing Program is a restricted distribution program that aims to ensure safe use of Tysabri, but it does not eliminate the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may require legal assistance to explore claims related to inadequate warning, failure to monitor, or failure to promptly diagnose and treat the condition.

Timeline of Exposure and Harm

The timeline between exposure to Tysabri and documented harm is variable. PML can occur at any time during treatment, but the risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Some cases have been reported after only a few doses, while others occur after many years of therapy. The onset of symptoms can be insidious, and the time from symptom onset to diagnosis can be prolonged if the condition is not suspected. Once PML is diagnosed, the prognosis is poor, with most patients experiencing significant neurological disability or death.

Summary of Risks and Legal Evaluation

In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The drug's labeling includes a boxed warning and identifies specific risk factors. Patients who develop PML may face life-altering consequences, and legal evaluation may be warranted to assess whether the risks were adequately communicated and managed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug's boxed warning highlights this risk, especially in patients with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML and how is it diagnosed?

PML symptoms include cognitive changes, motor weakness, gait disturbance, and visual impairments. Diagnosis requires brain MRI and detection of JCV DNA in cerebrospinal fluid. Because symptoms can mimic multiple sclerosis relapses, a high index of suspicion is necessary (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options do patients who develop PML after Tysabri have?

Patients may explore claims related to inadequate warning, failure to monitor, or failure to promptly diagnose PML. Legal evaluation can assess whether the prescribing physician adequately discussed risks and whether appropriate monitoring was performed under the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.